TISIDB

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF02270 Transcription initiation factor IIF
Function	TFIIF is a general transcription initiation factor that binds to RNA polymerase II and helps to recruit it to the initiation complex in collaboration with TFIIB. It promotes transcription elongation. This subunit shows ATP-dependent DNA-helicase activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000398 mRNA splicing, via spliceosome GO:0006352 DNA-templated transcription, initiation GO:0006354 DNA-templated transcription, elongation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0006368 transcription elongation from RNA polymerase II promoter GO:0006370 7-methylguanosine mRNA capping GO:0006397 mRNA processing GO:0008380 RNA splicing GO:0008543 fibroblast growth factor receptor signaling pathway GO:0009301 snRNA transcription GO:0009452 7-methylguanosine RNA capping GO:0016073 snRNA metabolic process GO:0019058 viral life cycle GO:0019080 viral gene expression GO:0019083 viral transcription GO:0031334 positive regulation of protein complex assembly GO:0032784 regulation of DNA-templated transcription, elongation GO:0032786 positive regulation of DNA-templated transcription, elongation GO:0032968 positive regulation of transcription elongation from RNA polymerase II promoter GO:0034243 regulation of transcription elongation from RNA polymerase II promoter GO:0036260 RNA capping GO:0042795 snRNA transcription from RNA polymerase II promoter GO:0043254 regulation of protein complex assembly GO:0043900 regulation of multi-organism process GO:0043902 positive regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044033 multi-organism metabolic process GO:0044089 positive regulation of cellular component biogenesis GO:0044344 cellular response to fibroblast growth factor stimulus GO:0046782 regulation of viral transcription GO:0048524 positive regulation of viral process GO:0050434 positive regulation of viral transcription GO:0050792 regulation of viral process GO:0060260 regulation of transcription initiation from RNA polymerase II promoter GO:0060261 positive regulation of transcription initiation from RNA polymerase II promoter GO:0071774 response to fibroblast growth factor GO:0098781 ncRNA transcription GO:1903900 regulation of viral life cycle GO:1903902 positive regulation of viral life cycle GO:2000142 regulation of DNA-templated transcription, initiation GO:2000144 positive regulation of DNA-templated transcription, initiation
Molecular Function	GO:0000990 transcription factor activity, core RNA polymerase binding GO:0000991 transcription factor activity, core RNA polymerase II binding GO:0004386 helicase activity
Cellular Component	GO:0000428 DNA-directed RNA polymerase complex GO:0005667 transcription factor complex GO:0005674 transcription factor TFIIF complex GO:0016591 DNA-directed RNA polymerase II, holoenzyme GO:0030880 RNA polymerase complex GO:0044798 nuclear transcription factor complex GO:0055029 nuclear DNA-directed RNA polymerase complex GO:0061695 transferase complex, transferring phosphorus-containing groups GO:0090575 RNA polymerase II transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03022 Basal transcription factors
Reactome	R-HSA-167242: Abortive elongation of HIV-1 transcript in the absence of Tat R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-112387: Elongation arrest and recovery R-HSA-6803529: FGFR2 alternative splicing R-HSA-1839126: FGFR2 mutant receptor activation R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat R-HSA-112382: Formation of RNA Pol II elongation complex R-HSA-113418: Formation of the Early Elongation Complex R-HSA-167158: Formation of the HIV-1 Early Elongation Complex R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-167169: HIV Transcription Elongation R-HSA-167161: HIV Transcription Initiation R-HSA-167287: HIV elongation arrest and recovery R-HSA-5663205: Infectious disease R-HSA-168254: Influenza Infection R-HSA-168255: Influenza Life Cycle R-HSA-168273: Influenza Viral RNA Transcription and Replication R-HSA-162599: Late Phase of HIV Life Cycle R-HSA-167290: Pausing and recovery of HIV elongation R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA R-HSA-77075: RNA Pol II CTD phosphorylation and interaction with CE R-HSA-167160: RNA Pol II CTD phosphorylation and interaction with CE during HIV infection R-HSA-167162: RNA Polymerase II HIV Promoter Escape R-HSA-674695: RNA Polymerase II Pre-transcription Events R-HSA-73776: RNA Polymerase II Promoter Escape R-HSA-73857: RNA Polymerase II Transcription R-HSA-75955: RNA Polymerase II Transcription Elongation R-HSA-75953: RNA Polymerase II Transcription Initiation R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening R-HSA-6807505: RNA polymerase II transcribes snRNA genes R-HSA-162582: Signal Transduction R-HSA-190236: Signaling by FGFR R-HSA-1226099: Signaling by FGFR in disease R-HSA-5654738: Signaling by FGFR2 R-HSA-8851708: Signaling by FGFR2 IIIa TM R-HSA-5655253: Signaling by FGFR2 in disease R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes R-HSA-167243: Tat-mediated HIV elongation arrest and recovery R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript R-HSA-167172: Transcription of the HIV genome R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-168325: Viral Messenger RNA Synthesis R-HSA-72086: mRNA Capping R-HSA-72172: mRNA Splicing R-HSA-72163: mRNA Splicing - Major Pathway R-HSA-72165: mRNA Splicing - Minor Pathway

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03022 Basal transcription factors

Reactome

R-HSA-167242: Abortive elongation of HIV-1 transcript in the absence of Tat
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-112387: Elongation arrest and recovery
R-HSA-6803529: FGFR2 alternative splicing
R-HSA-1839126: FGFR2 mutant receptor activation
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-113418: Formation of the Early Elongation Complex
R-HSA-167158: Formation of the HIV-1 Early Elongation Complex
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167161: HIV Transcription Initiation
R-HSA-167287: HIV elongation arrest and recovery
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-168273: Influenza Viral RNA Transcription and Replication
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167290: Pausing and recovery of HIV elongation
R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-77075: RNA Pol II CTD phosphorylation and interaction with CE
R-HSA-167160: RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
R-HSA-162582: Signal Transduction
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-8851708: Signaling by FGFR2 IIIa TM
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167243: Tat-mediated HIV elongation arrest and recovery
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-168325: Viral Messenger RNA Synthesis
R-HSA-72086: mRNA Capping
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
R-HSA-72165: mRNA Splicing - Minor Pathway

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GTF2F2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GTF2F2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GTF2F2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.676	0.031
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.86	0.722
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.542	0.76
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.08	0.727
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.102	0.942
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.054	0.976
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.116	0.749
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.415	0.794
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.237	0.891
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.063	0.963
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.484	0.808
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.081	0.21

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GTF2F2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GTF2F2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GTF2F2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GTF2F2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GTF2F2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GTF2F2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GTF2F2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GTF2F2
Name	general transcription factor IIF, polypeptide 2, 30kDa
Aliases	RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GTF2F2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse GTF2F2